SCHEDULE: Balyasny Asset Management Discloses Stake in Rallybio Corp

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 7.12% of Rallybio Corp's common stock as of March 31, 2026.

Summary

• Balyasny Asset Management L.P. (BAM), along with BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, collectively known as the Reporting Persons, have filed a Schedule 13G.
• The filing indicates beneficial ownership of 376,573 shares of Rallybio Corp's common stock.
• This ownership represents approximately 7.12% of the class of securities outstanding.
• The reporting date for this ownership is March 31, 2026.
• The shares are held by Atlas Diversified Master Fund, Ltd. (ADMF), an investment management client of BAM.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide new operational or financial performance data for Rallybio Corp.

Positives

• Significant stake acquired by a notable asset management firm, potentially indicating confidence in Rallybio's future prospects.
• The reporting is conducted in accordance with regulatory requirements, ensuring transparency for investors.

Risks

• The filing does not detail specific risks associated with Rallybio Corp, but any investment carries inherent market and company-specific risks.
• The beneficial ownership is held through various entities, which can add complexity to understanding direct control and decision-making.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Rallybio Corp. The future outlook for the company would be found in other SEC filings.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Balyasny Asset Management's increased interest in Rallybio Corp, a biotechnology company, which aligns with broader investment trends in the life sciences sector.

Stakeholder Impact

• Shareholders: Increased institutional ownership may influence stock liquidity and potentially signal investor confidence, though it does not directly impact current share value.
• Management: The filing acknowledges a significant ownership stake by an asset manager, which may lead to increased engagement on corporate strategy or governance matters.
• Creditors: No direct impact is indicated by this ownership filing.

Next Steps

• The Reporting Persons will continue to hold or manage their investment in Rallybio Corp.
• Further disclosures may be required if ownership levels change significantly.

Key Dates

Keywords

Rallybio Corp, Schedule 13G, Balyasny Asset Management, Beneficial Ownership, Common Stock, SEC Filing, Investment Management